Table 3.
Treatments received by treatment sequence in the new‐LUTS cohort
| Sequence of treatment received | |||
|---|---|---|---|
| Primary (N = 118 591) | Secondary (N = 15 237) | Tertiary (N = 7859) | |
| Time from index until treatment initiation, among those untreated at index (days) a (N = 107 671) | |||
| Median (Q1‐Q3) | 128 (21‐466) | ||
| Mean (95% CI) | 310 (306‐315) | ||
| Therapy | |||
| Antimuscarinics (monotherapy) | 4765 (4.0) | 3204 (21.0) | 709 (9.0) |
| Mirabegron (monotherapy) | 364 (0.3) | 459 (3.0) | 178 (2.3) |
| Multiple OAB | 0 (0) | 5 (0.0) | 26 (0.3) |
| OAB procedures (onabotulinumtoxinA, SNS, PTNS) | 0 (0) | 25 (0.2) | 12 (0.2) |
| Alpha‐blockers (monotherapy) | 91 167 (76.9) | 3967 (26.0) | 4960 (63.1) |
| 5‐Alpha reductase inhibitors (monotherapy) | 2530 (2.1) | 1253 (8.2) | 355 (4.5) |
| Tadalafil 2.5 mg or 5 mg (monotherapy) | 19 424 (16.4) | 2753 (18.1) | 854 (10.9) |
| BPH surgery | 0 (0) | 1552 (10.2) | 211 (2.7) |
| Multiple BPH | 239 (0.2) | 1297 (8.5) | 330 (4.2) |
| OAB + BPH | 102 (0.1) | 722 (4.7) | 224 (2.9) |
Abbreviations: BPH, benign prostate hyperplasia; CI, confidence interval; LUTS, lower urinary tract symptoms; OAB, overactive bladder; PTNS, percutaneous tibial nerve stimulation; Q, quartile; SNS, sacral neuromodulation.
a
Patients without corresponding line of therapies are excluded.